Market Research Partnership Connects Cannabis Sales Insights in CPG, Dispensaries, and Pharma
Our sister publication, Nutritional Outlook, recently published an article about market researchers BDSA and MSA and how they will provide cross-analysis of BDSA’s cannabis industry data, as well as, MSA’s CPG and healthcare data.
Two market researchers have formed a strategic alliance to enhance cannabis sales data. Cannabis industry market researcher BDSA (Louisville, CO) is partnering with Management Science Associates Inc. (MSA; Pittsburgh, PA), whose market research spans the CPG and healthcare sectors. Together, the firms say they will be able to offer cross-market data that “enables statistical analysis of consumers and delivers groundbreaking insights into the intersection of purchasing cannabis and pharmaceuticals for healthcare needs.”
Roy Bingham, BDSA’s cofounder and CEO, stated in a press release, “Our collaboration with MSA will revolutionize our clients’ understanding of how cannabis addresses diverse consumer needs. With half the population having consumed cannabis in the past six months, this is no longer a niche category only of interest to those within the industry. This partnership will provide actionable, revenue-driving audience, sales impact, and forecasting opportunities to companies inside and outside the cannabis industry.”
MSA is able to gather information on cannabis users in healthcare using its own, patented HIPPA-compliant method. The press release adds: “For the first time, statistically significant cannabis consumption and real-world healthcare data will be combined to identify the impact of cannabis consumption on consumer health and purchasing. Pharmaceutical, consumer packaged goods (CPG), government agencies, academia, healthcare, and cannabis companies eagerly anticipate these insights.” This includes companies who may be interested in getting involved with the cannabis market but who haven’t yet done so.
MSA’s clients will also gain more access to cannabis-industry insights. For instance, the press release states, “Manufacturers contemplating entry into the cannabis industry often face the challenge of limited visibility into cannabis dispensary sales. The integration of BDSA’s data with MSA’s reporting and analytical capabilities empowers manufacturers to target the right products to the right consumer audience, eliminating the guesswork.” Stephen Gongaware, MSA’s executive vice president of business development, added, “We are excited to partner with BDSA to expand our data portfolio to include critical sales insights from cannabis dispensaries.”
To read the full article, visit Nutritional Outlook: https://www.nutritionaloutlook.com/view/market-research-partnership-connects-cannabis-sales-insights-in-cpg-dispensaries-and-pharma
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
